GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Endoscopy/EUS-guided gallbladder drainage in acute cholecystitis

EUS-guided gallbladder drainage in acute cholecystitis

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated January 1, 2026

Quick Answer

EUS-guided gallbladder drainage (EUS-GBD) has emerged as a valuable and reliable treatment option for patients with acute cholecystitis who are considered high-risk for surgical intervention. Acute cholecystitis, an inflammation of the gallbladder typically caused by gallstones, can lead to serious complications if untreated.


EUS-guided gallbladder drainage (EUS-GBD) has emerged as a valuable and reliable treatment option for patients with acute cholecystitis who are considered high-risk for surgical intervention. Acute cholecystitis, an inflammation of the gallbladder typically caused by gallstones, can lead to serious complications if untreated. While surgery remains the standard treatment, certain patients, such as those with significant comorbidities or poor overall health, may not be suitable candidates for surgical procedures. In these cases, EUS-GBD provides an effective alternative.

EUS-GBD involves the use of endoscopic ultrasound to place a stent, creating a drainage pathway from the gallbladder to the gastrointestinal tract. This approach eliminates the need for external drainage, as seen in percutaneous transhepatic gallbladder drainage, and offers a minimally invasive solution with fewer complications. Guidelines now recommend EUS-GBD over percutaneous drainage due to its safety and efficacy.

Studies have shown that EUS-GBD achieves high rates of technical and clinical success, with durable outcomes over long-term follow-up. It is associated with low rates of adverse events, such as stent obstruction or infection, and provides effective symptom relief while reducing the need for repeat interventions or hospital readmissions. Overall, EUS-GBD represents a transformative option for managing acute cholecystitis in high-risk surgical patients.

Related Q&A

Duodenal Mucosal Resurfacing REMAIN-1 Study: DDW | 2026

Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...

EUS-FNAB for Solid Pancreatic Lesions: GIE | July 2026

Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...

Durable Endoscopic Partial Reversal of Roux-en-Y Gastric Bypass Using Parallel LAMS Septotomy: GIE | July 2026

Introduction: Although Roux-en-Y gastric bypass (RYGB) is an effective bariatric procedure, a small proportion of patients develop severe nutritional complications, refractory dumping syndrome, or other debilitating adverse events requiring reversal. This study describes a novel...

EUS Double Drainage for Malignant Dual Obstruction : Gut | Jul 2026

Introduction: Simultaneous malignant distal biliary obstruction (MDBO) and gastric outlet obstruction (GOO), commonly caused by advanced pancreatic, biliary, or duodenal cancers, presents a major palliative challenge. Conventional endoscopic approaches often require repeated interventions and may...

Endoscopic Mucosal and Submucosal Cutting in benign esophageal stricture: Gut | July 2026

Introduction: Long benign esophageal strictures remain one of the most difficult benign conditions to manage. Although endoscopic dilation and incision techniques provide temporary relief, recurrence is common, often requiring repeated interventions. This study introduces a...

Economic Impact of POEM and ESD: GIE | June 2026

Introduction: Peroral endoscopic myotomy (POEM) and endoscopic submucosal dissection (ESD) have revolutionized the management of esophageal motility disorders and early gastrointestinal neoplasia. Despite their proven clinical benefits, widespread adoption has been limited by concerns regarding...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer